Kraig Biocraft Laboratories In Stock Price, News & Analysis

Kraig Biocraft Laboratories (OTCQB: KBLB) announces that easing COVID-19 restrictions in Vietnam has revitalized its operations. The company, focused on spider silk production, faced delays due to pandemic restrictions, but is now poised to enhance silkworm production. Upcoming delivery of advanced quality control lab equipment will boost operational capabilities. With textile mills reopening, Kraig Labs is excited to resume the production of SpydaSilk apparel in partnership with Kings Golden Harvest, paving the way for new market opportunities.

Kraig Biocraft Laboratories (OTCQB: KBLB) has initiated challenge testing for its immunity-enhanced silkworms, designed to combat devastating viral and fungal infections impacting global silk production. With up to 50% of losses attributed to a specific virus affecting 75% of producers, Kraig Labs aims to license these disease-resistant silkworms to mitigate significant economic losses in the $14B silk industry. Successful testing could lead to commercial availability, further advancing their commitment to cost-effective and environmentally sustainable silk solutions.

Kraig Labs has filed a provisional patent for a groundbreaking gene-editing system that enhances the production of recombinant spider silk. This new knock-out/knock-in multiplex system significantly reduces process complexity by over 60%, potentially leading to higher yields. The research team is currently monitoring first-generation transgenics, with results expected in 30 days. Kraig Labs aims to apply this technology beyond silk, with implications for boutique protein production. COO Jon Rice highlighted the innovative team's achievements in unlocking cost-effective, commercial-scale production.

Kraig Biocraft Laboratories (OTCQB: KBLB) announced it will conduct challenge testing on two lines of immunity-enhanced silkworms to address significant losses in the silk industry caused by a widespread virus. Reportedly, 50% of silk production losses stem from this virus, affecting the economic viability of many producers. The company aims to license these transgenic silkworms globally, anticipating availability for commercial licensing post-successful testing. Kraig Labs continues to focus on the commercialization of eco-friendly recombinant spider silk.

Kraig Biocraft Laboratories (KBLB) has delivered its first fabric samples to Spydasilk Enterprises, marking a milestone in the development of spider silk apparel. The samples feature a blend of traditional silk and cotton, tailored to design specifications. The production will ramp up following approval, with plans to weave thousands of yards of fabric using recombinant spider silk. This delivery coincides with the reopening of the Vietnamese textile mill that produces the specialized silk, highlighting the company’s commitment to environmentally responsible apparel. Jon Rice, COO, views this as a crucial step towards commercialization.

Kraig Biocraft Laboratories (OTCQB: KBLB) has commenced the second generation of silkworm rearing at its new production facility for its Vietnamese subsidiary, Prodigy Textiles. Following a successful first batch in August, the new site improves access to mulberry supplies, reducing production costs. The easing of Covid-19 restrictions is facilitating the construction of finished goods, allowing Kraig Labs to expand its production of customized fabric blends for its Spydasilk brand. The company's initiatives aim to revolutionize global silk markets.

Kraig Biocraft Laboratories (KBLB) has secured patent protection for its recombinant spider silk technologies in the European Union, marking a significant milestone in the commercialization of spider silk. This patent allows the company to exert greater control over its revolutionary materials, with potential applications beyond textiles. The European silk market is projected to reach $2 billion by 2026. The company has also made breakthroughs in developing hydrolyzed spider silk, with details on commercialization expected soon.

Kraig Biocraft Laboratories (OTCQB: KBLB) announces the opening of a new spider silk production facility in Vietnam, a significant development in its operations. The custom-built, nearly 10-acre campus includes multiple production and research buildings, along with over 7 acres of mulberry cultivation fields. This site enhances operational efficiency by minimizing logistics costs for feedstock. Despite challenges due to COVID-19 affecting equipment procurement, production has transitioned smoothly, with ongoing expansions of rearing operations to bolster silk production.

Kraig Biocraft Laboratories (OTCQB: KBLB) has announced the addition of Dr. Jimi Miller as a senior scientist, effective July. His expertise in molecular biophysics and biochemistry is expected to enhance the company’s R&D efforts and commercialization of spider silk fibers. Dr. Miller has already contributed to filing two PCT patent applications and improved screening tools for transgenic development, crucial for large-scale production. The company aims to leverage his skills to innovate in spider silk technology, vital for the textile industry.